InMed Pharmaceuticals Inc INM

Healthcare Cannabis

InMed Pharmaceuticals Inc. is a pharmaceutical company. It develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharmaceuticals segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is cannabinoid analog being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a cannabinol topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.

NDAQ:INM - Post by User

InMed Pharmaceuticals Inc > Adams needs to be replaced

<< Previous

Bullboard Posts

Next >>

Comment by gainwidpatienceon Mar 31, 2021 8:50am

142 Views

Post# 32912639

RE:RE:Adams needs to be replaced

11 red candles on chart since Mar 15, which is a biggest red flag.. I have NEVER seen this while sp climbing up over the years.

IntegraSyn is a biggest lie. I have seen his interviews, presentations, recent filings. There is no info on how Inmed is going to materialize with $$ revenue or timelines. I am suspecting this is just a cash burning way to dilute more.

As per sedar filings, Eric takes more than $1m compensation.. which is easy money. Since last year, float has increased from 5m to 8m. If you look at the progress, hardly anything.

<< Previous

Bullboard Posts

Next >>

NTG Clarity Networks' growth story continues with $22M contract